Quad Medicine (464490) has 8 disclosed insider purchases and 0 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩379M ($263K) in reported transaction value. The earliest filing StockDrifts holds for Quad Medicine is dated 2025-12-12; the most recent is 2026-06-15. Across these filings the average return since disclosure is +1.77%, measured from each filing date to the latest available close.
| Date | Type | Source | Insider | Position | Shares | Price at filing | Return | Value |
|---|---|---|---|---|---|---|---|---|
| 2026-08-31 | BUY | Market Buy | 백승기 Baek Seung-gi | moving | 10.0K | ₩5,070 | -0.2% | ₩53M ($37K) |
| 2026-08-25 | BUY | 주식매수선택권 | 황근배 Hwang Geun-bae | moving | 10.0K | ₩5,120 | -1.2% | ₩41M ($28K) |
| 2026-08-25 | SELL | 기타 | 황근배 Hwang Geun-bae | moving | -10.0K | ₩5,120 | +1.2% | ₩51M ($36K) |
| 2026-07-22 | BUY | Market Buy | 백승기 Baek Seung-gi | CEO | 670 | ₩5,500 | +3.8% | ₩4M ($3K) |
| 2026-07-21 | BUY | Market Buy | 백승기 Baek Seung-gi | CEO | 1.2K | ₩5,620 | +1.6% | ₩7M ($5K) |
| 2026-07-20 | BUY | Market Buy | 백승기 Baek Seung-gi | CEO | 3.5K | ₩5,940 | -3.9% | ₩21M ($14K) |
| 2026-07-16 | BUY | Market Buy | 백승기 Baek Seung-gi | CEO | 1.8K | ₩6,000 | -4.8% | ₩11M ($8K) |
| 2026-07-15 | BUY | Market Buy | 백승기 Baek Seung-gi | CEO | 3.0K | ₩5,800 | -1.6% | ₩17M ($12K) |
| 2026-07-14 | BUY | Market Buy | 백승기 Baek Seung-gi | CEO | 5.2K | ₩5,400 | +5.7% | ₩28M ($20K) |
| 2026-06-15 | BUY | Market Buy | 백승기 Baek Seung-gi | CEO | 149 | ₩7,730 | +0.0% | ₩1M ($800) |
| 2026-06-12 | BUY | Market Buy | 백승기 Baek Seung-gi | CEO | 1.7K | ₩7,800 | -0.9% | ₩14M ($9K) |
| 2026-06-11 | BUY | Market Buy | 백승기 Baek Seung-gi | CEO | 1.9K | ₩7,780 | -0.6% | ₩15M ($10K) |
| 2026-06-10 | BUY | Market Buy | 백승기 Baek Seung-gi | CEO | 10.0K | ₩7,880 | -1.9% | ₩79M ($55K) |
| 2026-06-09 | BUY | Market Buy | 백승기 Baek Seung-gi | CEO | 11.4K | ₩7,630 | +1.3% | ₩87M ($60K) |
| 2026-04-24 | BUY | Market Buy | 백승기 Baek Seung-gi | CEO | 6.0K | ₩13,230 | +4.3% | ₩79M ($55K) |
| 2026-04-23 | BUY | Market Buy | 김영흥 Youngheung Kim | moving | 4.0K | ₩13,020 | +6.0% | ₩53M ($37K) |
| 2026-04-23 | BUY | Market Buy | 백승기 Baek Seung-gi | CEO | 4.0K | ₩13,020 | +6.0% | ₩52M ($36K) |
| 2026-02-02 | SELL | 기타 | 성길환 Seong Gil-hwan | moving | -13.5K | ₩15,000 | -15.3% | ₩203M ($141K) |
| 2026-02-02 | BUY | 주식매수선택권 | 성길환 Seong Gil-hwan | moving | 13.5K | ₩15,000 | +15.3% | ₩203M ($141K) |
| 2026-02-02 | BUY | 주식매수선택권 | 김영흥 Youngheung Kim | moving | 18.0K | ₩15,000 | +15.3% | ₩270M ($188K) |
| 2026-02-02 | SELL | 기타 | 김영흥 Youngheung Kim | moving | -18.0K | ₩15,000 | -15.3% | ₩270M ($188K) |
| 2026-02-01 | BUY | 신규선임 | 조현종 Hyeonjong Cho | moving | 10.0K | ₩15,000 | +15.3% | ₩150M ($104K) |
| 2026-01-01 | BUY | 신규선임 | 나운성 Naunseong | moving | 25.2K | ₩14,500 | +19.3% | ₩365M ($254K) |
| 2025-12-31 | SELL | 임원퇴임 | 허혜진 Hyejin Heo | moving | -5.9K | ₩14,500 | -19.3% | ₩85M ($59K) |
| 2025-12-12 | BUY | 신규상장 | 성길환 Seong Gil-hwan | moving | 13.5K | ₩17,630 | -1.9% | ₩238M ($165K) |
| 2025-12-12 | BUY | PROGRAM | 현신애 Hyun Shin-ae | moving | 48.3K | ₩17,630 | -1.9% | ₩852M ($591K) |
| 2025-12-12 | BUY | PROGRAM | 백승기 Baek Seung-gi | CEO | 2.2M | ₩17,630 | -1.9% | ₩38.5B ($26.7M) |
| 2025-12-12 | BUY | PROGRAM | 전혜선 Jeon Hye-sun | moving | 52.5K | ₩17,630 | -1.9% | ₩926M ($643K) |
| 2025-12-12 | BUY | PROGRAM | 박정환 Park Jeong-hwan | CTO | 441.0K | ₩17,630 | -1.9% | ₩7.8B ($5.4M) |
| 2025-12-12 | BUY | PROGRAM | 김영흥 Youngheung Kim | moving | 18.0K | ₩17,630 | -1.9% | ₩317M ($220K) |
| 2025-12-12 | BUY | PROGRAM | 김영흥 Youngheung Kim | moving | 45.0K | ₩17,630 | -1.9% | ₩793M ($551K) |
| 2025-12-12 | BUY | PROGRAM | 황근배 Hwang Geun-bae | moving | 10.0K | ₩17,630 | -1.9% | ₩176M ($122K) |
| 2025-12-12 | BUY | PROGRAM | 황근배 Hwang Geun-bae | moving | 10.0K | ₩17,630 | -1.9% | ₩176M ($122K) |
| 2025-12-12 | BUY | PROGRAM | 허혜진 Hyejin Heo | moving | 5.9K | ₩17,630 | -1.9% | ₩104M ($72K) |
| 2025-12-12 | BUY | 신규상장 | 성길환 Seong Gil-hwan | moving | 66.8K | ₩17,630 | -1.9% | ₩1.2B ($818K) |
Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.